Phase 2Completed
Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans
Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: A Phase 2, Single-Center, 20-week, Open-Label, Randomized Controlled Trial.
- Sponsor
- Sundeep Khosla, M.D. (Academic or other)
- Enrolment
- 74 enrolled
- Conditions
- Healthy
- Interventions
- Dasatinib; Quercetin; Fisetin
- Ages
- adults, older adults
- Registry
- NCT04313634
From the registry
To determine if senolytic drugs reduce senescent cell burden and reduce bone resorption markers/increase bone formation markers in elderly women.
Primary outcomes
- Change in C-terminal Telopeptide of Type I Collagen [CTX]